Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Estrogen receptor alpha (ERα) is a well-established therapeutic target for the treatment of
ER-positive (ER+) breast cancers. Despite the tremendous successes achieved with …

Endocrine therapy (ET) is a pivotal strategy to manage early-and advanced-stage estrogen
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …

Cancer drug resistance presents a major barrier to continued successful treatment of
malignancies. Current therapies inhibiting proteins indicated in cancer progression are …

Anticancer-targeted therapies inhibit various kinases implicated in cancer and have been
used in clinical settings for decades. However, many cancer-related targets are proteins …

The estrogen receptor (ER) is an important driver in the proliferation, tumorigenesis, and
progression of breast cancers, and targeting ER signaling at different levels is a successful …

Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of
cancer death among women worldwide. Globally, BC is the second most frequent cancer …

Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease
and the leading cause of cancer mortality in women. Advances in molecular technologies …

ESR1 mutation (ESR1 m) is a frequent cause of acquired resistance to aromatase inhibitor
(AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy …